High-activity Blood Coagulation Factor XI Mutant Ala570Thr Patent
Summary
The USPTO granted patent US12605430B2 to Ruijin Hospital Shanghai Jiaotong University School of Medicine for a high-activity blood coagulation factor XI mutant (Ala570Thr/A570T). The mutant demonstrates resistance to physiological inhibitors after activation and exhibits strong blood coagulation activity. The patent covers nucleotide sequences (SEQ ID NOs: 1-4), amino acid sequence (SEQ ID NO: 5), and applications for treating hemorrhagic diseases through gene therapy, gene editing, and recombinant protein replacement treatments.
What changed
The USPTO issued patent US12605430B2 for a high-activity blood coagulation factor XI mutant with the Ala570Thr substitution, covering the mutant's nucleotide and amino acid sequences along with its therapeutic applications. The patent was filed on April 13, 2021, with 5 claims granted.
Pharmaceutical and biotechnology companies developing treatments for hemorrhagic diseases, particularly those pursuing gene therapy, gene editing, or recombinant protein approaches targeting blood coagulation, should review this patent for freedom-to-operate considerations. The assignee's broad claim language covering multiple therapeutic modalities may affect competitive R&D programs in this coagulation factor space.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
High-activity blood coagulation factor XI mutant Ala570Thr
Grant US12605430B2 Kind: B2 Apr 21, 2026
Assignee
RUIJIN HOSPITAL SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
Inventors
Wenman Wu, Xuefeng Wang, Qiulan Ding
Abstract
A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.
CPC Classifications
C07K 14/745 A61K 38/36 A61K 38/4846 A61K 38/39 A61K 38/40 C12N 9/6443 C12Y 304/21027 A61P 7/04
Filing Date
2021-04-13
Application No.
18025398
Claims
5
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.